Get to Know Dr. Anastasios Dimou
Medical oncologist and associate professor Dr. Anastasios Dimou has been a leader in advancing the treatment of thoracic malignancies, including small cell lung cancer and pleural mesothelioma, at the Mayo Clinic in Rochester, Minnesota.
He has done extensive research and authored several papers on the tumor microenvironment, tumor immunology and precision oncology, all of which has helped him better personalize treatment.
He also plays a key role in the lung cancer and melanoma specialty programs that have helped the Mayo Clinic maintain its status as one of the top hospitals in the U.S. for treating cancer.
He is the principal investigator of two clinical trials involving the treatment of metastatic melanoma.
Specialties of Dr. Anastasios Dimou
- Pleural mesothelioma
- Lung cancer
- Thymic malignancies
- Precision oncology
Dr. Anastasios Dimou’s Experience and Medical Education
- Mayo Clinic
- University of Colorado (Fellowship)
- Medical University of South Carolina (Fellowship)
- Albert Einstein Medical Center (Residency)
- Yale University School of Medicine (Research Fellow)
- University of Athens Medical School (M.D.)
Awards and Certifications
- Board certified in hematology, medical oncology and internal medicine
- Advanced course in basic and clinical immunology
- American Association for Cancer Research (Member)
- American Society of Clinical Oncology (Member)
- International Association for the Study of Lung Cancer (Member)
Publications of Dr. Anastasios Dimou
- Dimou, A. et al. (2021, January). HLA Class 1 Binding of Mutant EGFR Peptides in NSCLC is Associated with Improved Survival. Journal of Thoracic Oncology.
- Dimou, A. et al. (2020, May 25). Neuropilin-2b facilitates resistance to tyrosine kinase inhibitors in non-small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery.
- Dimou, A. & Camidge, D.R. (2019, August). Detection of NRG1 Fusions in Solid Tumors: Rare Gold? Clinical Cancer Research.
- Dimou, A. et al. (2019, May 6). Inhibition of the Hedgehog pathway in lung cancer. Lung Cancer.
Thank you for your feedback. Would you like to speak with a Patient Advocate?